Therapy Areas: Devices
Bioventus Launches Durolane SJ in Australia and New Zealand; Receives Expanded Indications for Durolane
13 August 2019 - - Dutch orthobiologic solutions specialist Bioventus is launching Durolane SJ (1mL), and has received expanded indications for Durolane, its single-injection joint-fluid osteoarthritis treatment, in Australia and New Zealand, the company said.

Both are hyaluronic acid -based products and available from LMT Surgical.

Durolane SJ has been approved by Australia's Therapeutic Goods Association and Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, and will launch in both countries later this year.

It is indicated for symptomatic treatment associated with mild to moderate OA pain in the ankle, elbow, wrist, fingers, and toes. 

Durolane SJ is also indicated for pain following joint arthroscopy in the presence of OA within three months of the procedure.

In addition, Durolane, which has been indicated for symptomatic treatment of mild to moderate knee OA pain in both countries for several years, received approval for expanded indications by both the TGA and MEDSAFE.

These include symptomatic treatment of mild to moderate hip OA and the symptomatic treatment associated with mild to moderate OA pain in the ankle, shoulder, elbow, wrist, fingers, and toes. 

Durolane is also indicated for pain following joint arthroscopy in the presence of OA within three months of the procedure.

OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues and HA-based products like Durolane, help manage OA pain for patients. 

Durolane is non-avian and based on the safe, natural and unique NASHA technology.

NASHA yields stabilized HA which is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint.

Durolane, which was designed as a single-injection HA and has more Level 1 clinical studies than any other single-injection HA, has also been proven to provide greater reduction in OA knee pain versus Synvisc-One.

It has longer lasting pain relief versus a steroid injection, is safe for repeated courses of therapy, and repeated use of Durolane does not increase the incidence of adverse events.

LMT Surgical is known for introducing innovative products and services to benefit the healthcare industry and the patient, supporting Orthopaedic, Neurosurgery, Plastics, Spine and ENT specialties.

Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely.

Its mission is to make a difference by helping patients resume and enjoy active lives.

The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing.

Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.

Risks can include transient pain, swelling and/or stiffness at the injection site. Indications presented are those approved in Australia; indications and product offerings vary by country.

Consult with your local Bioventus representative for approved use within your region of interest.
Login
Username:

Password: